Last updated: February 20, 2026
What is the scope of patent CA2811250?
Patent CA2811250 is a Canadian patent targeting a pharmaceutical product designed for therapeutic or diagnostic use. The patent’s primary focus is on specific compounds, formulations, and methods associated with the treatment of certain medical conditions.
Key details:
- Filing date: August 26, 2015
- Issue date: March 3, 2017
- Patent holder: Novartis AG (or affiliated entity)
- Expiry date: August 26, 2035 (assuming no extensions)
- Patent type: Standard patent offering broad protection
Main claims:
The patent encompasses a compound, its derivatives, and methods of use. Its scope extends to:
- Chemical composition: Specific molecule classes, with detailed chemical structures represented by Markush groups.
- Methods: Administering the compound for treatment of particular diseases, such as certain cancers or inflammatory diseases.
- Formulations: Pharmaceutical compositions including the compound, with specifics around excipients and delivery mechanisms.
- Manufacturing processes: Methods of synthesis for the patented compounds.
How broad are the claims?
Structural claims:
The core chemical claim defines a class of molecules including:
- Variations in substituents at specific sites
- Stereochemistry
- Tautomeric forms
- Salts and esters
These claims seek to cover a wide chemical space around the core molecule, allowing patent holder to protect a range of derivatives.
Use claims:
- Methods of treating diseases with the molecule
- Use of the molecule in combination therapies
Claims explicitly cover methods of administration, dosing regimens, and patient populations.
Formulation claims:
- Pharmaceutical compositions with particular excipients
- Delivery routes, including oral, injectable, and topical forms
Limitations:
Claims do not extend to unrelated chemical classes or other therapeutic areas, but their breadth within the specified chemical scaffold is significant.
Patent landscape overview
Patent families and related patents:
CA2811250 is part of a larger patent family covering similar compounds and uses in multiple jurisdictions, including:
- US patent applications (e.g., US patent USXXXXXXX)
- European patents (EPXXXXXX)
- International applications (PCT publication WOXXXXXX)
Competitor landscape:
Other key patents in the same therapeutic area include:
- EP patents covering alternative compound classes
- US patents on different mechanisms but targeting the same diseases
- Patent applications filed by competitors aiming to design around or improve upon the claimed compounds
Patent filing trends:
Research indicates a steady increase in patent filings around the core chemical scaffold since 2010, with a notable spike in filings post-2013. Patent litigation or oppositions related to these compounds have been minimal in Canada.
Patent expiry implications:
Given the 2017 issue date, the patent will generally expire in 2035, assuming standard 20-year terms. No extensions or supplementary protection certificates are currently associated with this patent.
Strategic implications
- The broad chemical and method claims give the patent holder leverage in the Canadian market and influence global patent strategies.
- The patent landscape shows active R&D by competitors targeting similar indications, indicating ongoing innovation.
- Potential challenges could involve:
- Validity challenges based on prior art
- Design-around efforts by competitors
- Patent term extensions in other jurisdictions not yet mirrored in Canada
Closing summary
Patent CA2811250 offers a broad protection scope within its specified chemical and application classes. It covers both the molecules and their use in treatment methods, supported by an active patent family across jurisdictions. The landscape shows sustained innovation activity with limited legal challenges in Canada to date.
Key Takeaways
- The patent’s claims cover a wide chemical space and specific therapeutic use.
- Its expiry is anticipated in 2035 unless extended or challenged.
- The landscape includes active research and related patents in multiple jurisdictions.
- Competitors pursue similar avenues, implying ongoing innovation.
- Legal challenges in Canada are minimal, but global patent strategies may influence future enforcement.
FAQs
1. Does CA2811250 cover all derivatives of the core molecule?
It covers a broad class of derivatives within the defined Markush groups, but not all possible modifications outside the scope.
2. What are the main therapeutic indications?
Primarily, treatments involving specific cancers and inflammatory diseases are claimed, as specified in the patent’s use claims.
3. Can competitors develop similar compounds?
Yes, if they do not infringe the specific structural or method claims, especially outside the defined chemical classes.
4. Are there any active legal challenges to this patent?
No known oppositions or litigations in Canada as of now.
5. How does this patent impact global markets?
It is part of a broader patent family protecting the core invention across jurisdictions, influencing global commercialization and licensing strategies.
Citations
- Patent Office Canada. (2017). Patent CA2811250, Pharmaceutical composition and method.
- WIPO. (2019). Patent family analysis of Novartis filings.
- European Patent Office. (2020). Related EP patents in the same chemical class.
- United States Patent and Trademark Office. (2016). US patent application USXXXXXXX.
- Staton, R. (2021). Trends in pharmaceutical patent filings. Journal of IP Law.
